Ameritas Advisory Services LLC lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX – Free Report) by 8.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 6,657 shares of the medical equipment provider’s stock after purchasing an additional 524 shares during the period. Ameritas Advisory Services LLC’s holdings in Boston Scientific were worth $340,000 as of its most recent filing with the SEC.
A number of other large investors also recently added to or reduced their stakes in the business. International Assets Investment Management LLC bought a new position in shares of Boston Scientific during the first quarter valued at about $54,000. Acadian Asset Management LLC bought a new position in Boston Scientific during the 1st quarter worth approximately $35,000. Prudential PLC purchased a new position in Boston Scientific in the 1st quarter worth approximately $1,076,000. Cetera Investment Advisers lifted its position in Boston Scientific by 24.0% in the first quarter. Cetera Investment Advisers now owns 28,793 shares of the medical equipment provider’s stock valued at $1,275,000 after purchasing an additional 5,581 shares during the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Boston Scientific during the first quarter valued at approximately $230,000. Hedge funds and other institutional investors own 92.20% of the company’s stock.
Analyst Ratings Changes
BSX has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft upped their price target on shares of Boston Scientific from $45.00 to $55.00 in a report on Thursday, April 27th. StockNews.com assumed coverage on Boston Scientific in a report on Thursday, May 18th. They set a “buy” rating on the stock. Raymond James increased their price objective on Boston Scientific from $56.00 to $60.00 and gave the stock a “strong-buy” rating in a report on Monday, April 17th. 22nd Century Group reissued an “initiates” rating on shares of Boston Scientific in a research note on Friday, June 30th. Finally, BTIG Research raised their price target on Boston Scientific from $56.00 to $57.00 in a research note on Monday, July 17th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $56.95.
Boston Scientific Price Performance
Boston Scientific (NYSE:BSX – Get Free Report) last released its quarterly earnings data on Wednesday, April 26th. The medical equipment provider reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The business had revenue of $3.39 billion during the quarter, compared to analyst estimates of $3.16 billion. Boston Scientific had a net margin of 6.91% and a return on equity of 14.57%. Boston Scientific’s revenue was up 12.0% compared to the same quarter last year. During the same period last year, the business earned $0.39 EPS. As a group, equities analysts expect that Boston Scientific Co. will post 1.95 EPS for the current fiscal year.
Insider Activity at Boston Scientific
In other news, EVP Joseph Michael Fitzgerald sold 63,339 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $53.60, for a total value of $3,394,970.40. Following the completion of the transaction, the executive vice president now owns 213,859 shares in the company, valued at $11,462,842.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Boston Scientific news, EVP Eric Francis Yves Thepaut sold 83,401 shares of Boston Scientific stock in a transaction that occurred on Tuesday, May 2nd. The shares were sold at an average price of $52.49, for a total value of $4,377,718.49. Following the completion of the sale, the executive vice president now owns 12,269 shares of the company’s stock, valued at approximately $643,999.81. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 63,339 shares of the stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $53.60, for a total value of $3,394,970.40. Following the transaction, the executive vice president now directly owns 213,859 shares in the company, valued at $11,462,842.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 176,779 shares of company stock valued at $9,371,164. 0.71% of the stock is owned by corporate insiders.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Read More
- Five stocks we like better than Boston Scientific
- MarketBeat Week in Review – 7/17 – 7/21
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX – Free Report).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
